论文部分内容阅读
目的观察莫西沙星联合抗结核药治疗耐药性结核的临床效果。方法抽选医院2014年5月-2016年5月收治的耐药性结核患者72例,按照单双号将其均分为观察组和对照组各36例。对照组患者给予常规抗结核药治疗,观察组患者给予莫西沙星联合抗结核药治疗,对比分析2组疗效及不良反应。结果观察组患者的总有效率为86.11%明显高于对照组的63.89%,差异有统计学意义(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论临床治疗耐药性结核患者可采用莫西沙星联合抗结核药治疗,能有效提高治疗效果,不良反应发生率低,具有较高的临床应用价值,值得推广使用。
Objective To observe the clinical efficacy of moxifloxacin combined with anti-tuberculosis drug in the treatment of drug-resistant tuberculosis. Methods Seventy-two patients with drug-resistant tuberculosis admitted to the hospital from May 2014 to May 2016 were divided into observation group and control group according to single and double numbers respectively. Patients in the control group were given conventional antituberculosis drugs. Moxifloxacin and anti-tuberculosis drugs were given to the observation group. The curative effect and adverse reactions of the two groups were compared. Results The total effective rate in observation group was significantly higher than that in control group (86.11% vs 63.89%, P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Clinical treatment of patients with drug resistant tuberculosis can be treated with moxifloxacin combined with anti-TB drugs, can effectively improve the treatment effect, the incidence of adverse reactions is low, with high clinical value, it is worth promoting the use of.